Pa. Ganz et al., LIFE AFTER BREAST-CANCER - UNDERSTANDING WOMENS HEALTH-RELATED QUALITY-OF-LIFE AND SEXUAL FUNCTIONING, Journal of clinical oncology, 16(2), 1998, pp. 501-514
Purpose: To describe the health related quality of life (HRQL), partne
r relationships, sexual functioning, and body image concerns of breast
cancer survivors (BCS) in relation to age, menopausal status, and typ
e of cancer treatment. Patients and Methods: A cross-sectional sample
of BCS in two large metropolitan areas was invited to participate in a
survey study that included the following standardized measures: the R
AND 36-item Health Survey; the Centers for Epidemiologic Studies-Depre
ssion Scale (CES-D); the Dyadic Adjustment Scale (DAS): the Breast Can
cer Prevention Trial (BCPT) Symptom Checklist; the Watts Sexual Functi
oning Questionnaire (WSFQ); and subscales from the Cancer Rehabilitati
on Evaluation System (CARES). Results: Eight hundred sixty-four BCS co
mpleted the survey RAND Health Survey scores were as good or better th
an those of healthy, age-matched women, and the frequency of depressio
n was similar to general population samples. Marital/partner adjustmen
t was similar to normal healthy samples, and sexual functioning mirror
ed that of healthy, age-matched postmenopausal pausal women. However,
these BCS reported higher rates of physical symptoms (eg, joint pains,
headaches, and hot flashes) than healthy women. Sexual dysfunction oc
curred more frequently in women who had received chemotherapy (all age
s), and in younger women who were no longer menstruating. In women gre
ater than or equal to 50 years, tamoxifen therapy was unrelated to sex
ual functioning. Conclusion: BCS report more frequent physical and men
opausal symptoms than healthy women, yet report HRQL and sexual functi
oning comparable to that of healthy, age-matched women. Nevertheless,
some survivors still experience poorer functioning, and clinicians sho
uld inquire about common symptoms to provide symptomatic management or
counseling for these women. (C) 1998 by American Society of Clinical
Oncology.